These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9834819)

  • 1. Response rate as an endpoint for evaluating new cytotoxic agents in phase II trials of non-small-cell lung cancer.
    Sekine I; Kubota K; Nishiwaki Y; Sasaki Y; Tamura T; Saijo N
    Ann Oncol; 1998 Oct; 9(10):1079-84. PubMed ID: 9834819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive disease rate as a surrogate endpoint of phase II trials for non-small-cell lung cancer.
    Sekine I; Tamura T; Kunitoh H; Kubota K; Shinkai T; Kamiya Y; Saijo N
    Ann Oncol; 1999 Jun; 10(6):731-3. PubMed ID: 10442198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib.
    Tsujino K; Kawaguchi T; Kubo A; Aono N; Nakao K; Koh Y; Tachibana K; Isa S; Takada M; Kurata T
    J Thorac Oncol; 2009 Aug; 4(8):994-1001. PubMed ID: 19633474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of non-small-cell lung cancer in North America: the emerging role of irinotecan.
    Langer CJ
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):19-24. PubMed ID: 11221017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer.
    Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Wenger M; Lange W; Mertelsmann R
    Ann Oncol; 1997 Jan; 8(1):57-64. PubMed ID: 9093708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival.
    Lilenbaum RC; Langenberg P; Dickersin K
    Cancer; 1998 Jan; 82(1):116-26. PubMed ID: 9428487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
    Langer F; Helsberg K; Schütte WH; Leschinger MI
    Onkologie; 2005 Mar; 28 Suppl 1():1-28. PubMed ID: 15802886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel (Taxotere) in the treatment of non-small cell lung cancer (NSCLC)--is there a role for a new chemotherapy programme?
    Armand JP
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():223-30. PubMed ID: 10895158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
    Belani CP
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New options in the treatment of non-small cell lung cancer.
    Fossella F; Rigas JR; Belani CP
    Anticancer Drugs; 1999 Nov; 10 Suppl 1():S25-8. PubMed ID: 10630365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel (taxotere) in the treatment of non-small cell lung cancer.
    Georgoulias V
    Curr Med Chem; 2002 Apr; 9(8):869-77. PubMed ID: 11966449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer.
    Adjei AA; Argiris A; Murren JR
    Semin Oncol; 1999 Oct; 26(5 Suppl 16):32-40; discussion 41-2. PubMed ID: 10585007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
    Herbst RS
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-surgical therapy for patients with advanced non-small cell lung cancer.
    Liao M
    Respirology; 1998 Sep; 3(3):151-7. PubMed ID: 9767613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
    Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The current status of docetaxel for advanced non-small cell lung cancer.
    Green MR
    Anticancer Drugs; 2001 Feb; 12 Suppl 1():S11-6. PubMed ID: 11340898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vinorelbine (Navelbine) in non-small cell lung cancer: future directions.
    Crawford J
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):85-8. PubMed ID: 7526468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.
    Clark JI; Kancharla K; Qamar R; Fisher S; Hantel A; Panganiban J; Millbrandt L; Albain KS
    Lung Cancer; 2001 Nov; 34(2):271-7. PubMed ID: 11679186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New directions for chemotherapy in non-small-cell lung cancer.
    Green MR
    Chest; 1993 Apr; 103(4 Suppl):370S-372S. PubMed ID: 8096453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of two phase III randomized trials of single-agent docetaxel in previously treated advanced non--small cell lung cancer.
    Lynch TJ
    Semin Oncol; 2001 Jun; 28(3 Suppl 9):5-9. PubMed ID: 11444253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.